CAR T

CGT-19 as an approach to expand CAR T-cell therapy accessibility

Mon, 30 Mar 2026 09:00:00 -0400

The use of CAR T-cell therapy has transformed outcomes for relapsed or refractory B-cell malignancies, but access to it remains extremely limited in some countries. Cartogene Therapeutics Pvt Ltd. aimed to address this need by in-licensing CGT-19, a CD19 CAR T construct from Vector Biomed Inc.

CAR T targeting CD44E splicing variant shows potential for HCC treatment

Fri, 27 Mar 2026 09:00:00 -0400

Previously, Chinese researchers used long-read RNA sequencing to identify a unique alternative splicing variant of CD44 transmembrane protein, named CD44E, which is highly expressed in hepatocellular carcinoma (HCC) tumors compared to adjacent nontumoral liver tissues. In a new study, the team analyzed the Genotype-Tissue Expression (GTEx) database and confirmed that CD44E expression is limited in essential normal organs, while CD44S standard isoform is broadly expressed on most cell types.

Approach to enhance CAR T efficacy in infectious diseases and cancer

Thu, 26 Mar 2026 09:00:00 -0400

CAR T-cell therapy can be applied to treat some chronic infectious diseases, particularly to provide a functional cure for HIV-1 in people living with HIV. However, the effectiveness of CAR T cells for persistent suppression of HIV still faces many constraints, including the high mutation rate of reverse transcriptase, which enables the emergence of immune escape viral variants.

Overt Bio advances OVT-101 toward clinic

Tue, 24 Mar 2026 09:00:00 -0400

Overt Bio Inc. is advancing lead asset OVT-101 toward the clinic. The allogeneic, potential first-in-class, off-the-shelf γδ CAR T therapy targets claudin-6, which is present in the majority of ovarian cancers and several other solid tumors.

Nanobody CAR construct targeting CLL-1 shows preclinical activity against AML

Wed, 18 Mar 2026 09:00:00 -0400

Researchers from the Sino-American Cancer Foundation and Taipei Medical University have developed a novel nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1) for the possible treatment of acute myeloid leukemia (AML).

DR5 as promising CAR T-cell target allowing inhibition of tumor cells and MDSCs

Wed, 11 Mar 2026 09:00:00 -0400

University of Pennsylvania researchers investigated death receptor 5 (DR5 or CD262) as a chimeric antigen receptor (CAR) target for solid tumors.

HITting solid tumors with a closer look and a stronger CAR T cell

Mon, 02 Mar 2026 08:00:00 -0500

CAR T cells have been groundbreaking for the treatment of B-cell cancers. But 8 years after Kymriah (tisagenlecleucel, Novartis AG) became the first CAR T-cell therapy to be approved, there are no CAR Ts approved for solid tumors.

Nanobody-based CLL-1-targeted CAR T cells enhance AML killing with reduced off-target effects

Thu, 26 Feb 2026 08:00:00 -0500

To overcome the challenges of current CAR T-cell strategies and enhance their efficacy and specificity for acute myeloid leukemia, researchers at the Sino-American Cancer Foundation and collaborating institutions have developed a nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1).

TRX-319 silences autoreactive B and T cells in multiple sclerosis

Wed, 11 Feb 2026 08:00:00 -0500

Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.

Tempest Therapeutics outlines plans for acquired CAR T assets

Wed, 11 Feb 2026 08:00:00 -0500

Tempest Therapeutics Inc. has outlined plans to advance its newly acquired CAR T assets. While prioritizing development of its clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 (ERI-2003), the company will also expand its portfolio into next-generation modalities.

In vivo CAR T cells reduce liver fibrosis

Mon, 02 Feb 2026 08:00:00 -0500

Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha. This strategy not only reduced fibrosis but also reversed liver damage.

Selective CAR T targeting mutant CALR shows preclinical activity against MPNs

Wed, 28 Jan 2026 08:00:00 -0500

Despite the successful application of adoptive T-cell transfer with chimeric antigen receptor (CAR)-engineered T cells for the treatment of various hematologic malignancies, several other hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), still lack effective treatment options.

In vivo CAR T cells reduce liver fibrosis

Tue, 27 Jan 2026 08:00:00 -0500

Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha (FAP). This strategy not only reduced fibrosis but also reversed liver damage.

Dispatch Bio’s DISP-10 gains IND clearance for solid tumors

Tue, 13 Jan 2026 08:00:00 -0500

Dispatch Biotherapeutics Inc. has obtained IND clearance from the FDA for DISP-10, enabling the initiation of a phase I study in patients with solid tumors. Initial clinical evaluation will begin in gastrointestinal cancers, with plans to expand into multiple additional solid tumor indications following clinical proof of concept.

Development and characterization of anti-CD19 in vivo CAR T therapy

Mon, 29 Dec 2025 08:00:00 -0500

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR T candidate, named GT-801.

IMV-101 shows promise for B-cell malignancies

Wed, 24 Dec 2025 08:00:00 -0500

IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and autoimmune diseases. The company has presented results of the evaluation of its in vitro and in vivo properties.

Further financing at Vyriad to advance VV-169 into clinic

Wed, 24 Dec 2025 08:00:00 -0500

Vyriad Inc. has announced the closing of a $25 million final tranche to its series B financing, bringing the total series B round to $85 million. This additional funding will support first-in-human testing of VV-169, Vyriad’s in vivo CAR T candidate, in patients with relapsed or treatment-refractory multiple myeloma.

AERA-109 successfully fights B-cell-mediated autoimmune disorders

Wed, 17 Dec 2025 08:00:00 -0500

Researchers from Aera Therapeutics Inc. reported the preclinical profile of AERA-109, a novel, targeted in vivo CAR T therapy designed to treat B-cell-mediated autoimmune diseases.

Allogeneic CAR-NKT cells potent against primary and metastatic pancreatic cancer

Mon, 15 Dec 2025 08:00:00 -0500

Pancreatic cancer is a leading cause of cancer-related deaths worldwide and presents a 5-year survival rate of under 12%. Most patients are diagnosed at an advanced stage, with over half of them presenting with metastatic disease at diagnosis.

Avencell’s AVC-203 cleared for clinic for B-cell malignancies

Fri, 05 Dec 2025 08:00:00 -0500

Avencell Therapeutics Inc. has received clinical trial clearances from the FDA and EMA to conduct a phase I/II trial (Quadvance) of AVC-203 for the treatment of relapsed or refractory B-cell malignancies.

Targeting tenascin-C enhances survival in glioblastoma studies

Wed, 03 Dec 2025 08:00:00 -0500

Glioblastomas (GBMs) are the most prevalent and highly lethal primary brain tumors and currently rely on limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell-surface antigens have shown promise in GBM patients, inducing transient tumor regression. However, the lack of known tumor-restricted antigens in GBM limits further improvement of their therapeutic efficacy.

CRAFT CAR T cells: Using CRISPR with reduced off-target risks

Mon, 01 Dec 2025 08:00:00 -0500

Allogeneic CAR T-cell therapy offers several advantages over an individualized autologous CAR T approach, thanks to the use of readily available, higher quality and quantity of starting donor T cells and the potential to generate multiple doses from a single manufacturing process.

Scientists rehabilitate disease-causing T cells into tolerance builders

Tue, 04 Nov 2025 08:00:00 -0500

For 75 years, the standard tools for autoimmune disease have consisted of steroids, cytotoxics and broad biologics that tamp down the entire immune system. They can help, but they are rarely curative. “They’re blunt instruments,” Regcell Inc. CEO Mike McCullar told BioWorld. “They can’t distinguish good immune cells and bad immune cells,” which is why many carry black-box warnings and must be taken for years, sometimes for life.

Scientists rehabilitate disease-causing T cells into tolerance builders

Mon, 03 Nov 2025 08:00:00 -0500

Epigenetic switch and gene editing activate human T cells

Fri, 24 Oct 2025 09:00:00 -0400

Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the University of California San Francisco have stably silenced or activated genes in this type of immune cell without cutting or altering its DNA, making T cells more resistant, active, and effective against tumors.

SLC7A11 CAR T-cells show activity in solid tumor models

Wed, 22 Oct 2025 09:00:00 -0400

In a recent publication in iScience, researchers from Peking University First Hospital investigated the therapeutic potential of SLC7A11 CAR T therapy for solid tumors, particularly colorectal and pancreatic cancers.

Epigenetic switch and gene editing activate human T cells

Wed, 22 Oct 2025 09:00:00 -0400

Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the University of California San Francisco (UCSF) have stably silenced or activated genes in this type of immune cell without cutting or altering its DNA, making T cells more resistant, active, and effective against tumors.

ROR2 confirmed as suitable target for CAR T in hematologic, solid tumors

Mon, 20 Oct 2025 09:00:00 -0400

Researchers have demonstrated the potential of ROR2-specific CAR T cells.

GPC2-targeted CAR T-cells show activity against medulloblastoma

Thu, 16 Oct 2025 09:00:00 -0400

Medulloblastoma (MB), the most common malignant pediatric brain tumor, represents about 20% of childhood central nervous system cancers.

Tr1x’s TRX-319 cleared for clinical trial in progressive MS

Wed, 15 Oct 2025 09:00:00 -0400

Tr1x Inc. has obtained IND clearance from the FDA for TRX-319, paving the way for initiation of a phase I/IIa study in progressive multiple sclerosis (MS) early next year. TRX-319 is designed to combine targeted B-cell control with active anti-inflammatory signaling and T-cell regulation, with the goal of restoring immune balance.